丹红注射液联合瑞舒伐他汀抗冠状动脉粥样硬化的作用机制研究

Mechanism for role of Danhong injection combined with rosuvastatin in patients with coronary atherosclerosis

目的明确丹红注射液联合瑞舒伐他汀在冠状动脉粥样硬化症患者中的药物作用机制。方法200例冠状动脉粥样硬化患者随机分为对照组(A组)、瑞舒伐他汀组(B组)、丹红注射液组(C组)、瑞舒伐他汀联合丹红注射液组(D组)。抽血各组患者血清并提取和分离淋巴细胞,分别采用流式细胞仪技术检测IFN-γ阳性淋巴细胞占T淋巴细胞总数的比率,采用Western-blotting法检测KCNA3蛋白表达,采用ELISA法检测血清TNF-α和oxLDL含量,采用生化分析仪检测血清TC、TG、LDL-c、HDL含量。结果B、C、D组血清中IFN-γ阳性淋巴细胞占T淋巴细胞总数的比率、TNF-a与A组相比较差异有统计学意义(P<0.05),D组与B组、C组相比较差异有统计学意义(P<0.05);在B、C和D组中HDL、TC、TG、oxLDL与A组相比较差异均有统计学意义(P<0.05),D组与B、C组相比较差异均有统计学意义(P<0.05);在B和D组中LDL-c水平与A组相比较差异有统计学意义(P<0.05);在B、C和D组中可见KCNA3蛋白表达均较A组降低,与A组相比较差异均有统计学意义(P<0.05);D组与B、C组相比较差异有统计学意义(P<0.05);B组与C组中所有检测指标相比较差异均无统计学意义(P>0.05)。结论丹红注射剂联合瑞舒伐他汀可以通过降低患者的血管内皮的炎症反应,降低患者的血脂水平,调节钾离子通道的敏感性,从而减轻血管内皮损伤,进一步改善患者血管的硬化程度,预防心律失常发生,有利于患者的临床症状改善及预后。

Objective To explain mechanism for role of Danhong injection combined with rosuvastatin in patients with coronary atherosclerosis(CAS).Methods Two hundred patients with CAS were divided into four groups:group A(control group),group B(rosuvastatin group),group C(Danhong injection group),and group D(Danhong injection combined with rosuvastatin group).The rate of IFN-γ positive cells in lymphocytes was detected by flow cytometer;the expression of KCNA3 was detected by Western-blotting;the contents of TNF-α and oxLDL were detected by ELISA;the levels of HDL,TC,TG,LDL-c were detected by biochemical analyzer in different groups.Results The rate of IFN-γ positive cells in lymphocytes and TNF-a level in group B,C,and D were lower than those in group A,there were statistically significant differences between group D and group B,C(P<0.05).The levels of HDL,TC,TG,oxLDL in group B,C,and D were different from those in group A,there were statistically significant differences between group D and group B,C(P<0.05).It was statistically significantly different for level of LDL-c between group B,D and group A(P<0.05).The expression of KCNA3 were lower in group B,C,D compared with group A(P<0.05),there were statistically significant differences between group D and group B,C(P<0.05).There were no statistically significant differences in all indexes between group B and group C(P>0.05).Conclusions Danhong injection combined with rosuvastatin can improve prognosis for patients with CAS by inhibiting plaque formation and decreasing vascular injury,to prevent arrhythmia.In addition,they can also alleviate inflammatory reaction of blood vessel and improve clinical discomfort for patients with CAS.